This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Study Preview



Study Title and Description

Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.



Key Questions Addressed
1 Among pregnant and postpartum women, what is the effectiveness of pharmacologic interventions on maternal outcomes 1a. Among those with a new or preexisting anxiety disorder? 1b. Among those with a new or preexisting depressive disorder? 1c. Among those with a new or preexisting bipolar disorder? 1d. Among those with new or preexisting schizophrenia?
  • Comments Comments (
    0
    ) |
2 Among pregnant and postpartum women, what is the comparative effectiveness of pharmacologic interventions on maternal outcomes 2a. Among those with a new or preexisting anxiety disorder? 2b. Among those with a new or preexisting depressive disorder? 2c. Among those with a new or preexisting bipolar disorder? 2d. Among those with new or preexisting schizophrenia?
  • Comments Comments (
    0
    ) |
3 Among reproductive-aged women with any mental health disorder, what are the maternal and fetal harms associated with pharmacologic interventions for a mental health disorder during preconception, pregnancy, and postpartum?
  • Comments Comments (
    0
    ) |
4 Among reproductive-aged women with any mental health disorder, what are the comparative maternal and fetal harms of pharmacologic interventions for a mental health disorder during preconception, pregnancy, and postpartum?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.
Author Winterfeld U., Klinger G., Panchaud A., Stephens S., Arnon J., Malm H., Te Winkel B., Clementi M., Pistelli A., Maňáková E., Eleftheriou G., Merlob P., Kaplan YC., Buclin T., Rothuizen LE.
Country From the *STIS and Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland; †BELTIS Rabin Medical Center and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel; ‡School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland; §UKTIS, Regional Drug and Therapeutics Centre, Newcastle-Upon-Tyne, United Kingdom; ∥The Israeli Teratology Information Service, Israel Ministry of Health, Jerusalem, Israel; ¶Teratology Information Service, Helsinki University Central Hospital and HUSLAB, Helsinki, Finland; #TIS, Netherlands Pharmacovigilance Centre Lareb, Den Bosch, The Netherlands; **Servizio di Informazione Teratologica, Padova; ††Centro di Riferimento Regionale di Tossicologia Perinatale, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; ‡‡CZTIS, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; §§Poison Control, Bergamo, Italy; and ∥∥Terafar-Izmir Katip Celebi University Teratology Information, Training and Research Center, Izmir, Turkey.
Year 2015
Numbers Pubmed ID: 25830592

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Extraction Form
Design Details
Question... Follow Up Answer Follow-up Answer




Results & Comparisons

No Results found.